Evolus: "Extra-Strength" Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II

 

• “Extra-strength” 40U formulation achieves one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance
• Results indicate a favorable safety profile; no serious adverse events reported and 88% of all adverse events were mild
• Potential new “extra-strength” formulation would expand Evolus' Jeuveau^® offering
• Trial completion expected mid-2023; final results anticipated to be presented in 2H 2023

https://www.biospace.com/article/releases/-extra-strength-formulation-of-jeuveau-demonstrates-effects-lasting-26-weeks-in-interim-phase-ii-data-results-representing-prolonged-6-month-performance/